Ontario First Nations 'keep coming hat in hand' despite being treated 'like gold,' Doug Ford says
TORONTO — Ontario Premier Doug Ford says he is willing to give First Nations what they want for their support in developing mines, but they cannot 'keep coming hat in hand all the time to the government' for more money.
Article content
Ford is set to meet Thursday with several dozen chiefs who are part of Anishinabek Nation, which represents 39 First Nations in the province.
Article content
Article content
First Nations are livid with the province over the passage of Bill 5, which gives cabinet the power to suspend municipal and provincial laws for chosen projects through the creation of so-called special economic zones.
Article content
Article content
The designation of these zones is part of a new omnibus law that Ford's government says is designed to speed up the construction of large infrastructure projects, particularly mines.
Article content
Article content
First Nations have said they want to be part of economic development, but they are outraged by the government's decision to proceed with legislation before consulting them.
Article content
Ford has repeatedly said that First Nation treaty rights will be respected and the government will fulfil its duty to consult them through a series of meetings this summer.
Article content
'This is like handing an opportunity on a silver platter to First Nations that, by the way, I have treated like gold,' Ford said Wednesday at an unrelated news conference.
Article content
As proof of his government's good will, Ford pointed to the province's $3 billion Indigenous financing program for loan guarantees to allow First Nations to become owners in big infrastructure projects, as well as $70 million to train Indigenous workers for jobs in construction, development and mining.
Article content
Article content
'When I first came into office, I told Minister (Greg) Rickford, 'Treat them well, give them what they need, whatever they want for them to prosper.' But there's going to be a point that you can't just keep coming hat in hand all the time to the government, you've got to be able to take care of yourselves,' Ford said.
Article content
Article content
'And when you literally have gold mines, nickel mines, every type of critical mineral that the world wants, and you're saying, 'No, no, I don't want to touch that, by the way, give me money' — not going to happen.'
Article content
Sol Mamakwa, the New Democrat who represents the Ring of Fire region and the lone First Nation member of the Ontario legislature, called out Ford's remarks.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
24 minutes ago
- Globe and Mail
Biochips Market Projected to Reach USD 37.73 Bn by 2032, Growing at 16.0% CAGR
Biochips Market, By Product Type (DNA Chips, Protein Chips, Lab-on-chip Tissue Arrays, Cell Arrays), By End User (Biotechnology and Pharmaceutical Companies, Academic & Research Institutes, Hospitals and Diagnostic Centers, Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa) According to a recent report by Coherent Market Insights, Global Biochips market is estimated to be valued at USD 13.34 Bn in 2025 and is expected to reach USD 37.73 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 16.0% from 2025 to 2032. Increasing application of biochips in the field of proteomics, genomics and drug discovery can drive the market growth. Extensive R&D activities in the field of healthcare and growing demand for point-of-care testing and diagnostics can also boost demand for biochips during the forecast period. Global Biochips Market Key Takeaways According to Coherent Market Insights (CMI), the global biochips market size is projected to grow at a robust CAGR of 16%, from USD 13.34 Bn in 2025 to USD 37.73 Bn by 2032. Based on product type, DNA chips segment is expected to account for over two-fifths of the global biochips market in 2025. By end user, biotechnology and pharmaceuticals segment will likely hold a market share of 35.1% by 2025. North America is anticipated to retain its dominance, holding a market share of nearly 2/5 in 2025. As per CMIs' new biochips market analysis, Asia Pacific is expected to experience fastest growth during the forecast period. Growing Demand for Personalized Medicine Boosting Market Growth Coherent Market Insights' latest biochips market research report highlights major factors driving industry growth. One such prominent growth factor is the increasing demand for personalized medicine. Biochips are a key enabling technology in personalized medicine. They enable rapid and accurate analysis of an individual's genetic and proteomic profiles. This supports pharmacogenomics, helps in creating tailored treatment plans, and facilitates targeted therapies. These capabilities are especially valuable in managing complex diseases such as cancer. Thus, growing interest in personalized medicine will continue to provide a strong impetus for the growth of biochips market in the coming years. High Cost of Biochips and Adoption of Alternative Technologies Limiting Market Growth The future biochips market outlook looks promising. However, high cost of bioships and associated equipment, along with growing usage of alternative technologies, remain a significant barrier to broader market growth. Biochips are quite expensive due to their complex manufacturing processes and the need for specialized instrumentation. This high cost limits their accessibility, particularly among small and mid-sized laboratories, thereby reducing overall biochips market demand. Many end users are turning to alternative technologies like immunoassays, qPCR, and next-generation sequencing (NGS) due to their accuracy and cost-efficiency. This trend may also negatively impact the biochips market growth in the coming years. Growing Adoption in Disease Diagnostics Creating Lucrative Growth Opportunities Biochips are being increasingly used in the diagnosis of cancer, genetic disorders, and infectious diseases due to their high accuracy and speed. Their rising adoption in disease diagnostics is expected to create lucrative growth opportunities for biochip manufacturers during the forecast period. Rising incidence of chronic and infectious diseases, such as COVID-19, is creating a strong need for rapid diagnostics. This is expected to drive demand for biochips, as they offer fast and multiplexed detection of pathogens, making them ideal for point-of-care testing. Get Up to 25% Discount on the US Tariff Impact Analysis Report: Impact of AI on the Biochips Market Artificial Intelligence (AI) is making a profound impact on the biochips market. It enhances data analysis, diagnostics, and personalized medicine. AI algorithms significantly improve the accuracy and speed of disease detection by rapidly interpreting complex biological data produced by biochips. This powerful combination accelerates drug discovery and enables real-time health monitoring. With ongoing advancements in AI, new applications and efficiencies are expected to emerge. This evolution is poised to propel the biochips market toward greater scalability and precision in delivering advanced healthcare solutions. Emerging Biochips Market Trends Growing trend of miniaturization is significantly impacting the biochips market value. Key manufacturers are focusing on developing compact biochips (e.g. lab-on-a-chip systems) with improved features for use in diagnostics, drug discovery, and personalized medicine. Expanding applications of biochips in drug discovery is expected to foster sales growth. Biochips are increasingly used in drug discovery processes, particularly for gene expression analysis, toxicity profiling, and target identification. These applications are crucial for accelerating pharmaceutical R&D, thereby driving market growth. There is a growing emphasis on studying genes and proteins to better understand disease mechanisms, identify potential therapeutic targets, and develop personalized medicine approaches. This will likely create a strong demand for biochips in high-throughput research. Shift toward point-of-care testing (POCT) is expected to create lucrative growth avenues for biochip companies. Portable biochips are being widely used in POCT devices for faster diagnostics at the patient's location. Ongoing advancements in biochip manufacturing will also support market expansion. Improvements in microfluidics, microarray technology, and semiconductor biochip development are significantly enhancing capabilities of biochips. Analyst's View ' The global biochips market is expected to record robust growth, owing to increasing incidence of chronic and infectious diseases, rising demand for personalized medicines, and advancements in biochip manufacturing,' said senior analyst Abhijeet Kale. Current Events and Their Impact on the Biochips Market Competitor Insights Key companies listed in biochips market report: - LinguaFlex - Inspire Medical Systems, Inc. - Medtronic - LivaNova PLC - SomnoMed - Nihon Kohden Corporation - Siesta Medical Inc. - ResMed - Koninklijke Philips N.V. - Somnowell - Nyxoah SA - Fisher & Paykel Healthcare Limited - VYAIRE - Natus Medical Incorporated - Nox Medical - Drive DeVilbiss International - CLEVELAND MEDICAL DEVICES INC. - Advanced Brain Monitoring, Inc. - CONTEC MEDICAL SYSTEMS CO., LTD Key Developments In January 2025, Coherent Corp launched its new pinhole array biochips. These biochips are specifically designed for medical diagnostics, with a strong focus on gene sequencing applications. In May 2025, Archer Materials Limited partnered with Paragraf Limited for Biochip development. This partnership is intended to help Archer advance its Biochip for at-home testing of chronic kidney disease. Market Segmentation By Product Type DNA Chips Cancer Diagnosis and Treatment Gene Expression SNP Genotyping Genomics Drug Discovery Agricultural Biotechnology Others Protein Chips Proteomics Expression Profiling Diagnostics HTS Others Lab-on-chip IVD & POC Others Tissue Arrays Cell Arrays By End User Biotechnology and Pharmaceutical Companies Academic & Research Institutes Hospitals and Diagnostic Centers Others About Us:Coherent Market Insights leads into data and analytics, audience measurement, consumer behaviors, and market trend analysis. From shorter dispatch to in-depth insights, CMI has exceled in offering research, analytics, and consumer-focused shifts for nearly a decade. With cutting-edge syndicated tools and custom-made research services, we empower businesses to move in the direction of growth. We are multifunctional in our work scope and have 450+ seasoned consultants, analysts, and researchers across 26+ industries spread out in 32+ countries. Media Contact Company Name: Coherent Market Insights Contact Person: Mr. Shah Email: Send Email Phone: + 12524771362 Address: 533 Airport Boulevard, Suite 400, Burlingame, CA 94010, United States Burlingame City: Burlingame State: California Country: United States Website:
CTV News
33 minutes ago
- CTV News
Trade dispute has businesses worried about summer
Winnipeg Watch The ongoing trade dispute between Canada and the U.S. has some businesses concerned about their summer season.
Globe and Mail
37 minutes ago
- Globe and Mail
AMC Networks Inc. Announces Pricing of Private Offering of $400 Million of 10.50% Senior Secured Notes due 2032
NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- AMC Networks Inc. ('AMC Networks' or the 'Company') (Nasdaq: AMCX) today announced that it has priced an offering of $400 million aggregate principal amount of 10.50% senior secured notes due 2032 (the 'Notes') in a private offering. The Notes will be unconditionally guaranteed, on a joint and several basis, by each of AMC Networks' existing and future domestic subsidiaries, subject to certain exceptions, on a senior secured basis. AMC Networks expects to use the net proceeds from the offering of the Notes, together with cash on hand or other immediately available funds, to (i) fund its tender offer (the 'Tender Offer') to purchase for cash up to $450,000,000 aggregate principal amount of its outstanding 4.25% Senior Notes due 2029, (ii) pay related premiums, fees and expenses incurred in connection with the offering of the Notes and the Tender Offer, and (iii) repurchase or repay other corporate indebtedness. AMC Networks is offering the Notes (and the related guarantees) pursuant to an exemption under the Securities Act of 1933, as amended (the 'Securities Act'). The initial purchasers of the Notes will offer the Notes only to persons reasonably believed to be qualified institutional buyers in reliance on Rule 144A under the Securities Act or outside the United States to certain persons in reliance on Regulation S under the Securities Act. The Notes have not been and will not be registered under the Securities Act or under any state securities laws. Therefore, the Notes may not be offered or sold within the United States to, or for the account or benefit of, any United States person unless the offer or sale would qualify for a registration exemption from the Securities Act and applicable state securities laws. This press release shall not constitute an offer to sell, the solicitation of an offer to buy or a notice of redemption for any securities nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction. About AMC Networks AMC Networks (Nasdaq: AMCX) is home to many of the greatest stories and characters in TV and film and the premier destination for passionate and engaged fan communities around the world. The Company creates and curates celebrated series and films across distinct brands and makes them available to audiences everywhere. Its portfolio includes targeted streaming services AMC+, Acorn TV, Shudder, Sundance Now, ALLBLK and HIDIVE; cable networks AMC, BBC AMERICA (which includes U.S. distribution and sales responsibilities for BBC News), IFC, SundanceTV and We TV; and film distribution labels Independent Film Company and RLJE Films. The Company also operates AMC Studios, its in-house studio, production and distribution operation behind acclaimed and fan-favorite original franchises including The Walking Dead Universe and the Anne Rice Immortal Universe; and AMC Networks International, its international programming business. Forward-Looking Statements This press release may contain statements that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements concerning the timing, terms and completion of the offering of the Notes, the anticipated use of proceeds from the offering of the Notes and the timing, terms and completion of the Tender Offer. Investors are cautioned that any such forward-looking statements are not guarantees of future performance or results and involve risks and uncertainties, and that actual results, developments or events may differ materially from those in the forward-looking statements as a result of various factors, including financial community perceptions of the Company and its business, operations, financial condition and the industries in which it operates and the factors described in the Company's filings with the Securities and Exchange Commission, including the sections titled 'Risk Factors' and 'Management's Discussion and Analysis of Financial Condition and Results of Operations' contained therein. The Company disclaims any obligation to update any forward-looking statements contained herein. Contacts
